UCB IN THE UK & IRELAND

OUR CORE BELIEF

At UCB, our core belief has remained constant for more than

90 YEARS

Everyone deserves to live the best life that they can, **AS FREE AS POSSIBLE** from the challenges and uncertainty of severe disease.

We put **PATIENTS AT THE CENTRE OF EVERYTHING WE DO.** We listen with intent and make bold choices to pursue what's right for them.

We are a leading investor in the UK and are committed to delivering excellence in FOUR KEY AREAS:

- 1 RESEARCH & DEVELOPMENT
- 2 PATIENTS
- 3 PEOPLE
- 4 SUSTAINABILITY



RESEARCH & DEVELOPMENT

Our scientists harness evidence-based science to deliver treatments and personalised services that address **patient needs**.

We have world class discovery, research, development and early manufacturing facilities, and consistently re-invest around a quarter of our revenue back into R&D.

We have announced a **£1 billion** investment over the next five years, including a **new science hub** in Windlesham.

We have conducted

172 trials in the UK, involving

5,100 patients across

464 trial sites since 2004.

PATIENTS

We support patients in overcoming the burdens of their disease, helping them live their best possible lives.




We have **collaborated closely with patients** and stakeholders to create digital solutions that aim to increase adherence and symptom tracking, and monitor disease progression.

We are **driving change** in clinical trials to meet patient needs.

We are **committed to being a partner to the NHS** and we recognise
the importance of working together
to **deliver innovative solutions** to
benefit patients.

PEOPLE

We inspire a culture of inclusion by providing equitable opportunities to all current and prospective employees.



Around 10% of UCB's global workforce are employed across the UK and Ireland.

We focus on offering **career opportunities to diverse groups**and embrace unique talents.

We aim to increase knowledge and interest in careers across Science, Technology, Engineering and Maths (STEM), and create opportunities for women in science.



SUSTAINABILITY

How we do business is important to us; we plan to deliver sustainable business growth and contribute to positive societal impact.

In the countries we operate in, **all patients** who need our medicines will have **access to them by 2030.**

BY 2030 WE AIM TO:



Reduce our global waste generation by 25% and water consumption by 20%.



Become carbon neutral.

INSPIRED BY PATIENTS. DRIVEN BY SCIENCE.



Whether in the **treatments we**develop, or in how we deliver
those treatments, patient input is
one of the main drivers behind
our decisions. This is how we can
continue to innovate with agility
and purpose, to pursue what's
right for those who live with
severe diseases.

